{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T05:58:15Z","timestamp":1648533495771},"reference-count":23,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMIR"],"published-print":{"date-parts":[[2020,1,6]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Positron-emission tomography (PET)\/computerized tomography (CT)\nwith 18F-fludeoxyglucose (FDG) has been come into use for risk assessment of Hodgkin lymphoma\n(HL) patients in recent years. The aim of our study is to evaluate the reliability of interim PET results\naccording to Deauville score (DS), and also to compared PET findings with tumor reduction\non CT.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Forty-two HL patients (median 39, range 19-75 y, 27 M, 15 F) were retrospectively\nevaluated with pre, interim and post-treatment PET\/CT imaging. PET\/CT imaging was obtained 60\nmin after the intravenous administration of 3.7-5.2 MBq\/kg 18F-FDG.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The negative predictive value of the interim PET was 89%. Four (10.5%) of the 38 interim\nPET-negative patients became post-treatment PET-positive. According to CT, 15 patients were in\ncomplete remission (CR), 27 (64.6%) patients were in partial remission (PR) or stable disease\n(SD).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The negative predictive value of interim PET was not satisfactory considering the\ntreatment rate of over 80% of HL. Additionally, high rate of interim PET-negative patients\u2019 conversion\nto PET-positive post-treatment state was considered as unexpected.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573405615666190206154847","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T13:32:50Z","timestamp":1549632770000},"page":"59-64","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Reliability of Interim PET\/CT in the Hodgkin Lymphoma"],"prefix":"10.2174","volume":"16","author":[{"given":"Rafet","family":"Eren","sequence":"first","affiliation":[{"name":"Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihan","family":"G\u00fcndo\u011fan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ceyda","family":"Aslan","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Ko\u00e7","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Hilmi","family":"Do\u011fu","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eermin","family":"Alt\u0131ndal","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman","family":"Yoku\u015f","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Suyan\u0131","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tevfik Fikret","family":"\u00c7ermik","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1182\/asheducation-2003.1.225","volume":"2003","author":"Diehl V.","year":"2003","unstructured":"Diehl V.; Stein H.; Hummel M.; Zollinger R.; Connors J.M.; Hodgkin\u2019s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology (Am Soc Hematol Educ Program) 2003,2003,225-247","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1182\/blood-2012-03-403790","volume":"120","author":"Gallamini A.","year":"2012","unstructured":"Gallamini A.; Kostakoglu L.; Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? Blood 2012,120(25),4913-4920","journal-title":"Blood"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S0140-6736(12)60035-X","volume":"380","author":"Townsend W.","year":"2012","unstructured":"Townsend W.; Linch D.; Hodgkin\u2019s lymphoma in adults. Lancet 2012,380(9844),836-847","journal-title":"Lancet"},{"key":"ref=4","year":"2018","unstructured":"National Comprehensive Cancer Network2018"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/annonc\/mdu181","volume":"25","author":"Eichenauer D.A.","year":"2014","unstructured":"Eichenauer D.A.; Engert A.; Andr\u00e9 M.; ESMO guidelines working group. Hodgkin\u2019s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014,25(3),70-75","journal-title":"Ann Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"Hasenclever D.","year":"1998","unstructured":"Hasenclever D.; Diehl V.; A prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease. N Engl J Med 1998,339(21),1506-1514","journal-title":"N Engl J Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3109\/10428194.2012.677535","volume":"53","author":"Meignan M.","year":"2012","unstructured":"Meignan M.; Gallamini A.; Itti E.; Barrington S.; Haioun C.; Polliack A.; Report on the third international workshop on interim positron emission tomography in lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 2012,53(10),1876-1881","journal-title":"Leuk Lymphoma"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","volume":"25","author":"Gallamini A.","year":"2007","unstructured":"Gallamini A.; Hutchings M.; Rigacci L.; Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007,25(24),3746-3752","journal-title":"J Clin Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1007\/s00259-003-1162-9","volume":"30","author":"Rankin S.C.","year":"2003","unstructured":"Rankin S.C.; Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging 2003,30,S56-S64","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=10","first-page":"223","author":"Gupta R.K.","year":"1999","unstructured":"Gupta R.K.; Gospodarowicz M.K.; Lister T.A.; Clinical evaluation and staging. Hodgkin\u2019s Disease 1999,223-240","journal-title":"Hodgkin\u2019s Disease"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1200\/JCO.1988.6.6.931","volume":"6","author":"Canellos G.P.","year":"1988","unstructured":"Canellos G.P.; Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988,6(6),931-933","journal-title":"J Clin Oncol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","volume":"7","author":"Lister T.A.","year":"1989","unstructured":"Lister T.A.; Crowther D.; Sutcliffe S.B.; Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting. J Clin Oncol 1989,7(11),1630-1636","journal-title":"J Clin Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"Barrington S.F.","year":"2014","unstructured":"Barrington S.F.; Mikhaeel N.G.; Kostakoglu L.; Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 2014,32(27),3048-3058","journal-title":"J Clin Oncol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"Cheson B.D.","year":"2014","unstructured":"Cheson B.D.; Fisher R.I.; Barrington S.F.; Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014,32,3059-3068","journal-title":"J Clin Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","volume":"99","author":"Gallamini A.","year":"2014","unstructured":"Gallamini A.; Barrington S.F.; Biggi A.; The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 2014,99(6),1107-1113","journal-title":"Haematologica"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","volume":"25","author":"Juweid M.E.","year":"2007","unstructured":"Juweid M.E.; Stroobants S.; Hoekstra O.S.; Imaging subcommittee of international harmonization project in lymphoma. use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007,25(5),571-578","journal-title":"J Clin Oncol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1182\/asheducation-2014.1.135","volume":"2014","author":"Evens A.M.","year":"2014","unstructured":"Evens A.M.; Kostakoglu L.; The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Hematology (Am Soc Hematol Educ Program) 2014,2014(1),135-143","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00259-016-3390-9","volume":"43","author":"Fallanca F.","year":"2016","unstructured":"Fallanca F.; Alongi P.; Incerti E.; Diagnostic accuracy of FDG PET\/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC). Eur J Nucl Med Mol Imaging 2016,43(10),1837-1848","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ajh.23994","volume":"90","author":"Rigacci L.","year":"2015","unstructured":"Rigacci L.; Puccini B.; Zinzani P.L.; The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). Am J Hematol 2015,90(6),499-503","journal-title":"Am J Hematol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.2967\/jnumed.113.120451","volume":"54","author":"Kostakoglu L.","year":"2013","unstructured":"Kostakoglu L.; Gallamini A.; Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift? J Nucl Med 2013,54(7),1082-1093","journal-title":"J Nucl Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/bjh.14292","volume":"175","author":"Mesguich C.","year":"2016","unstructured":"Mesguich C.; Cazeau A.L.; Bouabdallah K.; Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol 2016,175(4),652-660","journal-title":"Br J Haematol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2967\/jnumed.113.130609","volume":"55","author":"Rossi C.","year":"2014","unstructured":"Rossi C.; Kanoun S.; Berriolo-Riedinger A.; Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med 2014,55(4),569-573","journal-title":"J Nucl Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/bjh.14902","volume":"179","author":"Milgrom S.A.","year":"2017","unstructured":"Milgrom S.A.; Pinnix C.C.; Chuang H.; Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone? Br J Haematol 2017,179(3),488-496","journal-title":"Br J Haematol"}],"container-title":["Current Medical Imaging Formerly Current Medical Imaging Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T19:03:08Z","timestamp":1581102188000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169687\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573405615666190206154847","relation":{},"ISSN":["1573-4056"],"issn-type":[{"value":"1573-4056","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}